In the recent years, the diagnosis and treatment of breast cancer have taken huge steps, all due to many ongoing studies toward its improvement. Treatment and diagnosis are more advanced than before and have gotten more accurate, leading to better results in patients.
Early detection and treatment are displayed to lead better outcomes for women with cancer, yet precisely detecting and diagnosing breast cancer stays extremely challenging. An x-ray of the breasts, or a mammogram, is used by clinicians to determine cancers early, but breast screening is not exact. Per year, thousands of cases are not picked up by mammograms, which include 30 percent of cancers that develop in the middle of screenings, while instances of overdiagnosis or false alarms are usual.
Breast cancer is the most common type of cancer among women around the world. It is also the most diagnosed cancer in women and the second leading cause of death in women in the United States. A woman is diagnosed with breast cancer every two minutes, and every 13 minutes, one woman dies from it.
Image source: Chicago.suntimes.com
Having these facts in mind, Welwaze Medical, Inc, has developed Celbrea TMD, which is a safe, reliable, and affordable way to routinely monitor for breast abnormalities, including breast cancer. It is a non-invasive test that can be used for breast self-exams at home when prescribed by doctors. Celbrea TMD was developed and designed to help detect breast diseases by recording the temperature differentiation between corresponding areas of the left and the right breasts.
Alex J. Ness is the Executive Chairman of Welwaze Medical, Inc, a health tech company that develops external sensors that allow users to monitor their health. Since 2016, Welwaze has acquired intellectual property for its revolutionary early breast cancer detection device. For more articles like this, follow this page.
No comments:
Post a Comment